Recurrent Skin Langerhan Cell Histiocytosis Successfully Treated With Indomethacin Monotherapy
Journal of pediatric hematology/oncology
Langerhans cell histiocytosis (LCH) often has a recurrent and refractory course despite multiagent treatment modalities. Common relapse treatments include intense or prolonged cytotoxic chemotherapy regimens. There are a few prior reports that the nonsteroidal anti-inflammatory drug indomethacin demonstrated activity against bone LCH. Here we report indomethacin as a successful treatment for a case of chronic skin LCH that failed multiple prior chemotherapy regimens. This experience supports the need for trials to investigate indomethacin as a treatment for LCH both in the relapsed or refractory setting as well as potential combination or maintenance therapy in newly diagnosed patients.
Dhir, Aditi; Kelly, David R.; Watts, Raymond G.; and Kutny, Matthew A., "Recurrent Skin Langerhan Cell Histiocytosis Successfully Treated With Indomethacin Monotherapy" (2020). School of Medicine Faculty Publications. 1747.